A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects With Early Alzheimer's Disease
Phase of Trial: Phase III
Latest Information Update: 28 Oct 2018
At a glance
- Drugs Elenbecestat (Primary)
- Indications Alzheimer's disease
- Focus Registrational; Therapeutic Use
- Acronyms MissionAD2
- Sponsors Eisai Co Ltd
- 31 Aug 2018 Biomarkers information updated
- 17 Jul 2018 Planned End Date changed from 1 Dec 2020 to 29 Mar 2021.
- 17 Jul 2018 Planned primary completion date changed from 1 Nov 2020 to 29 Mar 2021.